JP2015510935A - 封入ジエチレントリアミンペンタアセテート粒子の経口送達のための組成物および方法 - Google Patents

封入ジエチレントリアミンペンタアセテート粒子の経口送達のための組成物および方法 Download PDF

Info

Publication number
JP2015510935A
JP2015510935A JP2015501777A JP2015501777A JP2015510935A JP 2015510935 A JP2015510935 A JP 2015510935A JP 2015501777 A JP2015501777 A JP 2015501777A JP 2015501777 A JP2015501777 A JP 2015501777A JP 2015510935 A JP2015510935 A JP 2015510935A
Authority
JP
Japan
Prior art keywords
dtpa
composition
particles
less
average diameter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015501777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510935A5 (enExample
Inventor
ジェイムズ・デイビッド・タルトン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ology Bioservices Inc
Original Assignee
Nanotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanotherapeutics Inc filed Critical Nanotherapeutics Inc
Publication of JP2015510935A publication Critical patent/JP2015510935A/ja
Publication of JP2015510935A5 publication Critical patent/JP2015510935A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015501777A 2012-03-22 2013-03-14 封入ジエチレントリアミンペンタアセテート粒子の経口送達のための組成物および方法 Ceased JP2015510935A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261614333P 2012-03-22 2012-03-22
US61/614,333 2012-03-22
US201361771873P 2013-03-03 2013-03-03
US61/771,873 2013-03-03
PCT/US2013/031336 WO2013142258A1 (en) 2012-03-22 2013-03-14 Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles

Publications (2)

Publication Number Publication Date
JP2015510935A true JP2015510935A (ja) 2015-04-13
JP2015510935A5 JP2015510935A5 (enExample) 2016-05-12

Family

ID=48014341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501777A Ceased JP2015510935A (ja) 2012-03-22 2013-03-14 封入ジエチレントリアミンペンタアセテート粒子の経口送達のための組成物および方法

Country Status (8)

Country Link
US (1) US9040091B2 (enExample)
EP (1) EP2827853A1 (enExample)
JP (1) JP2015510935A (enExample)
KR (1) KR20140139563A (enExample)
AU (1) AU2013235491A1 (enExample)
CA (1) CA2867701C (enExample)
MX (1) MX2014011123A (enExample)
WO (1) WO2013142258A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018052884A (ja) * 2016-09-29 2018-04-05 菊川　正 放射線核種キレート化剤を内包する経口投与剤

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6649262B2 (ja) * 2014-02-18 2020-02-19 メデシス・ファルマ・ソシエテ・アノニムＭｅｄｅｓｉｓ Ｐｈａｒｍａ Ｓ．Ａ． 放射性核種及び金属のキレート剤を送達するための逆ミセルシステムの使用
CO2018004165A2 (es) 2015-10-23 2018-09-20 Vifor Int Ag Inhibidores de ferroportina
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
WO2024253935A1 (en) 2023-06-05 2024-12-12 Nanopharmaceutics, Inc. Compositions and methods for oral delivery of sustained release crystalline prx-3140

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516003A (ja) * 2001-12-10 2005-06-02 メルク　エンド　カムパニー　インコーポレーテッド タキキニン受容体アンタゴニストの薬学的ナノ粒子組成物
JP2009526853A (ja) * 2006-02-17 2009-07-23 エスアールアイ インターナショナル 放射性核種のキレート化のための経口ｄｔｐａ
WO2011133198A1 (en) * 2010-04-21 2011-10-27 Hosheng Tu A pharmaceutical composition of nanoparticles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US7910086B1 (en) * 2005-01-04 2011-03-22 Gp Medical, Inc. Nanoparticles for protein drug delivery
EP1922150A1 (en) 2005-07-07 2008-05-21 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516003A (ja) * 2001-12-10 2005-06-02 メルク　エンド　カムパニー　インコーポレーテッド タキキニン受容体アンタゴニストの薬学的ナノ粒子組成物
JP2009526853A (ja) * 2006-02-17 2009-07-23 エスアールアイ インターナショナル 放射性核種のキレート化のための経口ｄｔｐａ
WO2011133198A1 (en) * 2010-04-21 2011-10-27 Hosheng Tu A pharmaceutical composition of nanoparticles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018052884A (ja) * 2016-09-29 2018-04-05 菊川　正 放射線核種キレート化剤を内包する経口投与剤

Also Published As

Publication number Publication date
MX2014011123A (es) 2014-12-05
US9040091B2 (en) 2015-05-26
KR20140139563A (ko) 2014-12-05
CA2867701A1 (en) 2013-09-26
CA2867701C (en) 2020-10-27
US20130251815A1 (en) 2013-09-26
EP2827853A1 (en) 2015-01-28
WO2013142258A1 (en) 2013-09-26
AU2013235491A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
ES2812250T3 (es) Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
AU2007260822B2 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US20080102121A1 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
HUE028529T2 (en) A method for producing granules of a powdered organic compound
JP2015510935A (ja) 封入ジエチレントリアミンペンタアセテート粒子の経口送達のための組成物および方法
TW201114766A (en) Pharmaceutical composition for a hepatitis C viral protease inhibitor
CN101484170A (zh) 包含纳米颗粒萘普生和控释氢可酮的组合物
CN102946857A (zh) 制备意图口服给药的包含一种或多种活性成分的药物组合物的方法以及包含其的组合物
MX2011002847A (es) Polvo de compuesto organico combinado para uso medico y metodo de produccion y suspension del mismo.
JP4588791B2 (ja) 微粒子油性懸濁液を含む医薬組成物
US8741344B1 (en) Dispersible tablet
CN109496151A (zh) 用于治疗疼痛的塞来昔布口服组合物
CN110582278B (zh) 药物组合物及其用途
AU2013347264B2 (en) Dispersible tablet
ES2733113T3 (es) Composición farmacéutica estable de una sal de vinorelbina soluble en agua
WO2022072099A9 (en) Immediate release dosage forms, methods of making and using
BR112019016400A2 (pt) composições de complexos de gálio (iii) para administração oral
DK177906B1 (en) Dispersible tablet
US20150283083A1 (en) Dispersible Tablet
WO2024080884A1 (en) Pharmaceutical compositions of tretinoin and methods of producing such compositions
PAUL MASTER OF PHARMACY
CN112353759A (zh) 菲并吲哚里西啶生物碱衍生物纳米自乳化组合物及其制备方法
Jethara Patented Pharmaceutical Reconstitutable Sustained Release Suspension
JP2018044017A (ja) 粒子製剤
KR20170133575A (ko) 신규 반고형 제제

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170224

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170321

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20170725